Genotypic and Phenotypic Diversity as a Function of CRISPR-Directed Gene Knock-Out of NRF2 in Pancreatic Adenocarcinoma Cells, a Feasibility Study
London P. McGill, Kelly H. Banas, Gregory Tiesi, Eric B. Kmiec · 2026
Read Genotypic and Phenotypic Diversity as a Function of CRISPR-Directed Gene Knock-Out of NRF2 in Pancreatic Adenocarcinoma Cells, a Feasibility Study by London P. McGill, Kelly H. Banas, Gregory Tiesi, Eric B. Kmiec (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13297238.txt.
Description
London P. McGill and colleagues test CRISPR guides that knock out a drug-resistance gene in pancreatic cancer cells in a 2026 feasibility study. The gene, NRF2, acts as a master switch for cellular defences. Guides aimed at different parts of the gene were delivered into tumour cells and scored by genetic and functional tests.
Editing rates ranged widely between guides, with heavy random insertions and deletions at cut sites. Guides hitting three middle exons produced the strongest combined effects. Disrupting two of them cut cell survival and restored sensitivity to the chemotherapy drug gemcitabine. The authors identify the sweet spots for a deeper study of this resistance-breaking strategy.
Catalog record
| CREATOR | London P. McGill, Kelly H. Banas, Gregory Tiesi, Eric B. Kmiec |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |